CompletedNot Applicable

Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Thailand80 participantsStarted 2008-01

Plain-language summary

Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Impending recurrent pterygium developed within 6 months following pterygium surgery either simple excision or excision with grafting.
✓. Failure of conventional topical anti-inflammatory therapy for impending recurrent pterygium which was defined by the progression of fibrovascular tissue over the excised area despite receiving treatment.
✓. No history of any adjunctive treatment such as MMC, 5-FU, periocular injection of corticosteroids and beta radiation.
✓. No other ocular surface pathologies or coexisting ocular diseases.
✓. No other ocular surgeries within the previous 6 months.
✓. No history of allergy to the medications used in this study.
✓. Good compliance with the study regimen and availability for the duration of the entire study period.

Exclusion criteria

✕. Platelet disorders
✕. Hypertension
✕. Pregnant or lactating women

What they're measuring

Severity of impending recurrent pterygium

Timeframe: 3 months

Trial details

NCT IDNCT01288404

SponsorRamathibodi Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-09

View on ClinicalTrials.gov More Pterygium of the Conjunctiva and Cornea trials